Egalet Corporation has terminated a co-promotion agreement with Septodont, the company said, and is now partnered with Valeant’s OraPharma division for co-promotion of Sprix ketorolac tromethamine nasal spray to US dentists and oral surgeons.
Sprix has been approved by the FDA since 2010 for short-term treatment of moderate-to-severe pain. Under the terms of the 2-year deal, OraPharma will begin promoting the product in the first quarter of 2018.
Egalet Chief Operating Officer Mark Strobeck commented, “Given the need for additional non-narcotic analgesics in the dental space, we believe Sprix nasal spray offers an attractive product profile that can complement the OraPharma line of oral health products. This partnership, which expands our commercial reach, represents one aspect of our business development strategy which also includes acquisition of late-stage or approved assets and out-licensing of our Guardian Technology pipeline product candidates.”
Read the Egalet press release.
